Conventional therapeutic dosing of enoxaparin exposed people with obesity or renal impairment to more frequent above‐range anti‐factor‐Xa levels; individualizing the dose could improve this but might expose people to subtherapeutic levels. The gene discussed is TNXA; the disease is obesity disorder.